Protagenic Therapeutics, Inc.new (PTIX): Nasdaq/NYSE listing notice — Protagenic receives Nasdaq delisting notice for failing to regain $1 bid price compliance

Protagenic Therapeutics, Inc.new

Nasdaq notified on Jan 22, 2025 that company failed to regain compliance with minimum bid price Rule 5550(a)(2).
Company not eligible for second 180-day compliance period due to not meeting initial listing requirements.
Company will present to Nasdaq Hearings Panel on Jan 30, 2025; no immediate delisting effect.
Deficiency originally reported on July 24, 2024; stock closed below $1 for 30 consecutive business days.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 22, 2025, Nasdaq provided a notice to the Company that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comp

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 22, 2025, Nasdaq provided a notice to the Company that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. This notification is part of the ongoing discussions with the Nasdaq Hearings Panel (the “Panel”) regarding the Company’s listing status, and the Company will include this matter in its presentation to the Panel on January 30, 2025. Importantly, the notification letter has no immediate effect on the list

View on SEC.gov

Browse all listing & compliance notices →

Protagenic Therapeutics, Inc.new filing history →

Source: SEC EDGAR

accession 0001493152-25-004143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.